{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:52:20Z","timestamp":1793670740925,"version":"4.5.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ijcard.2013.07.113","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T21:02:58Z","timestamp":1377291778000},"page":"5126-5134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":256,"title":["High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy"],"prefix":"10.1016","volume":"168","author":[{"given":"Wolfgang","family":"Koenig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2013.07.113_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis \u2014 an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.ATV.0000251503.35795.4f","article-title":"Biomarkers of atherosclerotic plaque instability and rupture","volume":"27","author":"Koenig","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0020","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0025","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0030","series-title":"Health, United States, 2011: with special feature on socioeconomic status and health. Hyattsville, MD","author":"National Center for Health Statistics","year":"2012"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0035","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/hc0302.102575","article-title":"Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular M\u00fcnster (PROCAM) study","volume":"105","author":"Assmann","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0045","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0050","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: a method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0055","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","article-title":"A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry","volume":"291","author":"Eagle","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0060","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1093\/eurheartj\/ehs164","article-title":"Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score","volume":"33","author":"Goliasch","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0065","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","article-title":"Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK\u2013Belgian Study)","volume":"31","author":"Fox","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_rf0065","first-page":"1799","article-title":"Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis","volume":"294","author":"Danesh","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.07.113_rf0500","first-page":"2848","volume":"294","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11886-999-0069-x","article-title":"Fibrinolytic function and coronary risk","volume":"1","author":"Juhan-Vague","year":"1999","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0080","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199005313222201","article-title":"Platelet hyperreactivity and prognosis in survivors of myocardial infarction","volume":"322","author":"Trip","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0085","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0090","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.109.884866","article-title":"B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies","volume":"120","author":"Di Angelantonio","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0095","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMoa0805299","article-title":"A sensitive cardiac troponin T assay in stable coronary artery disease","volume":"361","author":"Omland","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0100","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1373\/clinchem.2012.183319","article-title":"Cardiac troponin T measured by a high-sensitivity assay predicts recurrent cardiovascular events in stable coronary heart disease patients with 8-year follow-up","volume":"58","author":"Koenig","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0065-2776(08)60379-X","article-title":"Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein","volume":"34","author":"Pepys","year":"1983","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0110","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0021-9150(00)00586-4","article-title":"Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study","volume":"154","author":"Pankow","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/bmm.11.108","article-title":"High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?","volume":"6","author":"Rietzschel","year":"2012","journal-title":"Biomark Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0125","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/01.CIR.0000033116.22237.F9","article-title":"Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells","volume":"106","author":"Venugopal","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0130","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/01.RES.0000147309.54227.42","article-title":"C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction","volume":"95","author":"Li","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0135","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.CIR.0000052617.91920.FD","article-title":"C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis","volume":"107","author":"Devaraj","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0140","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/eurheartj\/ehq238","article-title":"C-reactive protein is a mediator of cardiovascular disease","volume":"31","author":"Bisoendial","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0145","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/eurheartj\/ehp070","article-title":"C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction","volume":"30","author":"\u00d8rn","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.HYP.0000130484.20501.df","article-title":"C-reactive protein: risk marker or mediator in atherothrombosis?","volume":"44","author":"Jialal","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1373\/clinchem.2008.108886","article-title":"The evolving role of C-reactive protein in atherothrombosis","volume":"55","author":"Devaraj","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0160","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvp249","article-title":"C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction","volume":"84","author":"Devaraj","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0165","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/01.ATV.0000183718.62409.ea","article-title":"C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant","volume":"25","author":"Singh","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0170","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/01.RES.0000163015.67711.AB","article-title":"Activation of inflammation and coagulation after infusion of C-reactive protein in humans","volume":"96","author":"Bisoendial","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0175","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1161\/res.97.7.e71","article-title":"In response to van den Berg et al.: on the direct actions of CRP in humans","volume":"97","author":"Bisoendial","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0180","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1161\/01.RES.0000196746.75724.8b","article-title":"In vivo effects of C-reactive protein (CRP)-infusion into humans","volume":"97","author":"Bisoendial","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0185","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2350-10-46","article-title":"Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations","volume":"10","author":"Karakas","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.ijcard.2013.07.113_rf0195","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijcard.2013.07.113_rf0505","first-page":"356","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0205","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0210","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa0707064","article-title":"Use of multiple biomarkers to improve the prediction of death from cardiovascular causes","volume":"358","author":"Zethelius","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2009.943","article-title":"Novel and conventional biomarkers for prediction of incident cardiovascular events in the community","volume":"302","author":"Melander","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Emerging Risk Factors Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0225","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.jacc.2010.09.001","article-title":"2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"56","author":"Greenland","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.07.113_rf0225","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_rf0510","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/eurheartj\/ehs254","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0235","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Emerging Risk Factors Collaboration","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0240","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199408183310701","article-title":"The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina","volume":"331","author":"Liuzzo","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0245","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0140-6736(96)07591-5","article-title":"Production of C-reactive protein and risk of coronary events in stable and unstable angina","volume":"349","author":"Haverkate","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0250","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJM200010193431602","article-title":"Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease","volume":"343","author":"Lindahl","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0255","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1161\/01.CIR.0000012625.02748.62","article-title":"Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients","volume":"105","author":"Mueller","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0260","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1373\/clinchem.2006.080192","article-title":"Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome","volume":"53","author":"Apple","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0265","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.jacc.2008.03.019","article-title":"Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study","volume":"51","author":"Bogaty","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0270","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2796.2007.01871.x","article-title":"A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels","volume":"262","author":"Tello-Montoliu","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0275","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1373\/clinchem.2011.172940","article-title":"Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction","volume":"58","author":"Schaub","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0280","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/hrt.2009.174912","article-title":"Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies","volume":"96","author":"He","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0285","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/01.CIR.99.7.855","article-title":"Elevated levels of C-Reactive protein at discharge in patients with unstable angina predict recurrent instability","volume":"99","author":"Biasucci","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0290","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.atherosclerosis.2007.01.009","article-title":"Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina","volume":"196","author":"Niccoli","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0295","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0300","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0305","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0310","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/ATVBAHA.107.151787","article-title":"Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study","volume":"28","author":"Kinlay","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0320","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0140-6736(10)62174-5","article-title":"C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study","volume":"377","author":"Heart Protection Study Collaborative Group","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0325","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/eurheartj\/ehr262","article-title":"Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"33","author":"Sever","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0330","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/S0140-6736(11)60807-6","article-title":"C-reactive protein in the Heart Protection Study","volume":"377","author":"Ridker","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0335","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/eurheartj\/ehr310","article-title":"Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS\/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials","volume":"33","author":"Braunwald","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0340","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0345","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0350","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland Coronary Preventions Study","volume":"357","author":"Ford","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0355","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.5551\/jat.4606","article-title":"Neopterin and atherosclerotic plaque instability in coronary and carotid arteries","volume":"17","author":"Sugioka","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0360","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.2174\/092986709789878247","article-title":"The role of neopterin in atherogenesis and cardiovascular risk assessment","volume":"16","author":"Fuchs","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0365","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.amjcard.2003.07.031","article-title":"Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction","volume":"92","author":"van Haelst","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0370","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1093\/eurheartj\/ehq322","article-title":"Multiple marker approach to risk stratification in patients with stable coronary artery disease","volume":"31","author":"Schnabel","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0375","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1373\/clinchem.2008.118844","article-title":"Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study","volume":"55","author":"Grammer","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0380","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/eurheartj\/ehi111","article-title":"Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris","volume":"26","author":"Avanzas","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0385","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2010.07.006","article-title":"Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease","volume":"160","author":"White","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0390","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ahj.2011.07.018","article-title":"Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome","volume":"162","author":"O'Donoghue","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0395","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0400","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"IL6R Genetics Consortium Emerging Risk Factors Collaboration","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0405","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0410","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1161\/01.ATV.20.11.2394","article-title":"Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis","volume":"20","author":"Dewberry","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0415","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0420","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2353\/ajpath.2006.051054","article-title":"Interleukin-1\u03b2 and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice","volume":"168","author":"Chamberlain","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0425","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.CIR.0000085567.18648.21","article-title":"Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury","volume":"108","author":"Isoda","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0430","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/01.ATV.0000127025.48140.a3","article-title":"Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice","volume":"24","author":"Isoda","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0435","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cardiores.2005.01.008","article-title":"Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice","volume":"66","author":"Merhi-Soussi","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0440","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/01.CIR.97.3.242","article-title":"Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice","volume":"97","author":"Elhage","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0445","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1161\/01.CIR.0000142085.39015.31","article-title":"Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and\/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications","volume":"110","author":"Chi","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0450","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1172\/JCI118476","article-title":"Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor","volume":"97","author":"Shimokawa","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0455","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cardiores.2005.06.026","article-title":"Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model","volume":"68","author":"Morton","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0460","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1 beta in coronary arteries of patients with ischemic heart disease","volume":"16","author":"Galea","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0465","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0735-1097(00)01014-7","article-title":"Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting","volume":"36","author":"Kastrati","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0470","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/01.CIR.99.7.861","article-title":"Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease","volume":"99","author":"Francis","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0475","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1253\/circj.CJ-08-1150","article-title":"A functional inteleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1 beta: interleukin-1 receptor antagonist balance in atherosclerosis","volume":"73","author":"Olofsson","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0480","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomoditis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.07.113_bb0485","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527313013247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527313013247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T17:47:16Z","timestamp":1563731236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527313013247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0167527313013247"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2013.07.113","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2013.07.113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}